Welcome to Chiesi
Spain
Parma, April 26, 2017 - Chiesi, Farmaceutici, an international pharmaceutical company focused on research based in Parma, Italy, and present in 26 countries, closes 2016 with an annual turnover of 1,571 million euros, an increase of more than +7 , 0% compared to the previous year (+9.6% with a constant exchange rate) and EBITDA equivalent to 448 million euros (a year-on-year increase of more than 8.2%). The good health of the company is reflected in its investment in R & D that increases by more than + 12.5% in the 2015-2016 period to 340 million euros in 2016, 21% of total sales. The Group currently has 51 active research and development projects. The total number of employees now exceeds 4800: people as a central element, passion, entrepreneurial spirit and intercultural dialogue are the values on which the company will continue to base its development in the coming years.
"Our company is based on an entrepreneurial spirit that characterizes every aspect of our daily activities, as well as a constant commitment to innovation," says Alberto Chiesi, president of Grupo Chiesi. «This commitment has seen us grow following our mission to develop pharmaceutical solutions that improve the quality of human life. From a small laboratory in Parma, we have expanded our capabilities and our presence year after year to become one of the 50 most important pharmaceutical companies in the world. " Alberto Chiesi concludes, "a company is a community made up of people united by common objectives, who seek to provide goods and services in the territories in which the company operates, to achieve personal and corporate welfare and provide support for social life , cultural and economic areas that you can reach. We want to thank all of our people from the different departments of our headquarters as well as the subsidiaries for their passionate, intelligent and proactive participation in the growth of our business ».
The market for respiratory drugs is a key global player in which Chiesi is present, and some brands in its product portfolio continue to generate significant growth and revenue: Foster® (beclomethasone dipropionate and formoterol fumarate) generated sales by a value of 583 million euros, with an increase of 16.6% compared to 2015. Curosurf® (poractant alfa) has exceeded 209 million euros, 4.3% more than in 2015, confirming its global leadership as a medicine that contributes to saving lives in neonates. This drug, entirely developed and manufactured in Italy, is indicated for the treatment of respiratory distress syndrome, a rare disease that affects lung function in premature babies. Clenil® (beclomethasone dipropionate) generated sales of more than 174 million euros, a slight decrease compared to 2015 due to the negative impact of currency fluctuations.
The global presence of Chiesi is reflected by its international sales, which generated 83% of its turnover in 2016. European subsidiaries have experienced a general increase in turnover of 4.9%, reaching the milestone of one billion for the first time. time. Two of its acquisitions in the Europe region for 2016 were:
Atopix Therapeutics Ltd., a British biotechnology company that expands Chiesi's product portfolio in the field of respiratory diseases, especially the inflammatory respiratory eosinophilic disease.
Lipograsil from the Zambon Group, for Chiesi Spain, which produces a range of food supplements for weight control, and which positions the subsidiary in a key area of the Spanish sales segment of self-care products with a strong product already consolidated in the market.
In addition, Chiesi Italia, the Italian subsidiary of the Chiesi Group, has signed an agreement with Marco Antonetto for the distribution rights, in Italy, of a series of significant brands in the health sector of consumers, such as Digestivo Antonetto, Euchessina and Lievito Sohn. .
An agreement has also been reached with The Medicines Company for the acquisition of worldwide marketing rights for two hospital products, such as Kengreal® Cleviprex® and, for the US market, the injection of Argatroban. Kengreal® (cangrelor), Cleviprex® (clevidipino), already launched in the American market and some European countries, will complement the portfolio of products in the hospital environment.
Emerging markets have experienced outstanding growth, despite currency fluctuations that have inevitably affected the Group's economic growth: Brazil, Turkey, China, Pakistan and Mexico performed well and grew 14.5% in total. local currency.
2016 witnessed the submission to the European Medicines Agency (EMA) of the application dossiers for the authorization to commercialize two new drugs from the portfolio of products under development in the therapeutic areas of respiratory and rare diseases:
The first ICS / LABA / LAMA triple fixed combination, indicated for the treatment of chronic obstructive pulmonary disease (COPD) and administered by a single inhaler, specifically formulated by Chiesi in its Parma Research Center, ensures that the extra-fine particles arrive to the central airways and the small airway.
Velmanasa alfa, new biological entity and the second biotechnological product (after Holoclar®) for which Chiesi has submitted an application for marketing authorization through a centralized procedure. The drug consists of the human enzyme alpha-mannosidase and is produced with recombinant DNA technology. It is indicated for the treatment of severe and progressive disorder called alpha-mannosidosis, an extremely rare genetic defect that causes severe and debilitating bone abnormalities, deafness, recurrent infections and mental retardation.
"In 2016 we continued with our growth trajectory: following the steps of established products such as Foster, and through expansion in our therapeutic areas, Chiesi Group sales increased by almost 10% with constant exchange rates with respect to the previous year. . It is an important achievement in times of economic difficulty that makes us think that we are heading in the right direction. 2017 looks equally promising, "says Ugo Di Francesco, CEO of Grupo Chiesi. "Thanks to our triple fixed combination, whose marketing authorization is expected for this year, patients with COPD will have a single inhaler for the simultaneous administration of two bronchodilators and an anti-inflammatory for the first time. It is an important therapeutic innovation that allows the control of symptoms, as well as the prevention of exacerbations. And also thanks to our new enzyme replacement therapy, which once approved will represent the only hope for children and adults with a devastating disease for which currently there is no authorized medication available ».
